CellSource Co (TSE:4880) Gross-Profit-to-Asset % : 44.64% (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CellSource Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. CellSource Co's annualized Gross Profit for the quarter that ended in Jan. 2024 was 円3,055 Mil. CellSource Co's average Total Assets over the quarter that ended in Jan. 2024 was 円6,844 Mil. Therefore, CellSource Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2024 was 44.64%.

CellSource Co Gross-Profit-to-Asset % Historical Data

The historical data trend for CellSource Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellSource Co Gross-Profit-to-Asset % Chart

CellSource Co Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

90.86

60.03

72.55

76.94

55.49

CellSource Co Quarterly Data
	Oct18	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															69.16	66.15	72.32	50.68	44.64

Competitive Comparison of CellSource Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, CellSource Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CellSource Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where CellSource Co's Gross-Profit-to-Asset % falls into.

CellSource Co Gross-Profit-to-Asset % Calculation

CellSource Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Oct. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Oct. 2023 )	/	( (Total Assets (A: Oct. 2022 )	+	Total Assets (A: Oct. 2023 ))	/ count )
	=	3185	/	( (4599.68	+	6879.736)	/ 2 )
	=	3185	/	5739.708
	=	55.49 %

CellSource Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jan. 2024 )	/	( (Total Assets (Q: Oct. 2023 )	+	Total Assets (Q: Jan. 2024 ))	/ count )
	=	3055.224	/	( (6879.736	+	6807.595)	/ 2 )
	=	3055.224	/	6843.6655
	=	44.64 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jan. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

CellSource Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of CellSource Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

CellSource Co (TSE:4880) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002

Website

https://www.cellsource.co.jp

CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines